Clinical Trial

Assessing the Acceptability, Feasibility, Effectiveness and Cost-effectiveness of LADB

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The goal of the proposed study is to generate evidence on the acceptability, feasibility, effectiveness, and cost-effectiveness of introducing long-acting depot buprenorphine (LADB) as an additional option for the treatment of opioid dependence in low- and middle-income countries (LMIC) among people who inject drugs (PWID) with opioid dependence. The study results will be used to inform global and local policies and guidelines to introduce LADB as a treatment option and to advocate for access to a sustainable supply of LADB in LMIC.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-11-10; most recent amendment 2025-10-01.
Trial Details
NCT Number NCT06129916
Lead Sponsor PATH
Collaborators: UNITAID, World Health Organization, Médecins du Monde, Frontline AIDS, London School of Hygiene and Tropical Medicine, International Network of People who Use Drugs, Monash University, Population Services International, Burnet Institute, University of Bristol, Alliance for the Public's Health, Coact Technical Support Limited
Conditions Opioid Dependence
Enrollment 760 participants
Start Date 2025-11-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-10-07